Comparative Pharmacology
Head-to-head clinical analysis: NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE versus SUDAFED 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE versus SUDAFED 12 HOUR.
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE vs SUDAFED 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naphazoline is an alpha-adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness and edema. Pheniramine is a histamine H1-receptor antagonist that blocks the effects of histamine, reducing itching and allergic symptoms.
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
1-2 drops or sprays in each nostril every 4-6 hours as needed, not to exceed 5-7 days
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
None Documented
None Documented
Naphazoline: Terminal elimination half-life approximately 2-3 hours; clinical effects may persist longer due to local vasoconstriction. Pheniramine: Terminal elimination half-life approximately 14-16 hours; appropriate for twice-daily dosing.
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (CrCl <30 mL/min); shorter in children (3-4 hours)
Naphazoline: Renal excretion of unchanged drug and metabolites accounts for >80% of elimination. Pheniramine: Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with <5% biliary/fecal elimination.
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Category C
Category C
Ophthalmic Antihistamine/Decongestant
Decongestant